Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.

MLA

Hippisley-Cox, Julia, et al. “Risk of Severe COVID-19 Disease with ACE Inhibitors and Angiotensin Receptor Blockers: Cohort Study Including 8.3 Million People.” Heart, vol. 106, no. 19, Oct. 2020, pp. 1503–11. EBSCOhost, https://doi.org/10.1136/heartjnl-2020-317393.

APA

Hippisley-Cox, J., Young, D., Coupland, C., Channon, K. M., Pui San Tan, Harrison, D. A., Rowan, K., Aveyard, P., Pavord, I. D., Watkinson, P. J., & Tan, P. S. (2020). Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart, 106(19), 1503–1511. https://doi.org/10.1136/heartjnl-2020-317393

Chicago

Hippisley-Cox, Julia, Duncan Young, Carol Coupland, Keith M. Channon, Pui San Tan, David A. Harrison, Kathryn Rowan, et al. 2020. “Risk of Severe COVID-19 Disease with ACE Inhibitors and Angiotensin Receptor Blockers: Cohort Study Including 8.3 Million People.” Heart 106 (19): 1503–11. doi:10.1136/heartjnl-2020-317393.